Compare Chewy Inc (CHWY) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chewy Inc vs Heron Therapeutics Inc — how do they compare? Chewy Inc trades at $22.2 (market cap $9.20B), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: Chewy Inc is far larger — about 149.7× Heron Therapeutics Inc's market cap, and Chewy Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CHWY | HRTX | |
|---|---|---|
Market Cap | $9.20B | $61.47M |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $1.49 |
52-Week Low | $17.51 | $0.32 |
Enterprise Value | $9.16B | $168.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chewy (CHWY) trades at $22.16, down 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though the net margin remains thin at 1.99%. Recent news highlights insider sales and institutional position changes, while analyst consensus remains strongly bullish with an 81.58% buy rating and a $33.82 price target.
The outlook is mixed: strong revenue growth and high ROE support upside potential, but thin margins, competitive pressures, and recent insider selling pose risks. Earnings beats in recent quarters provide momentum, yet the stock faces volatility near key support at $22. Investors should weigh robust analyst optimism against execution challenges in the pet care market.
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
